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Abstract. Four terpenoid derivatives were examined for their activity against Trypanosoma cruzi.Our results show that
two compounds were very active in vitro against both extra- and intracellular forms. These compounds, non-toxic for the host
cells, are more effective than the reference drug benznidazole. The capacity to infect cells was negatively affected and the number
of amastigotes and trypomastigotes was reduced. A wide range of ultrastructural alterations was found in the epimastigote
forms treated with these compounds. Some metabolic changes occurred presumably at the level of succinate and acetate
production, perhaps caused by the disturbance of the enzymes involved in sugar metabolism inside the mitochondria. In vivo
results were consistent with those observed in vitro. The parasitic load was significantly lower than in the control assay with
benznidazole. The effects of these products showed the reduction of the anti-T. cruzi antibodies level during the chronic stage.
INTRODUCTION
Tropical and subtropical diseases caused by protozoal
parasites remain a major public health problem in many of
the less developed countries of the world, because of the
lack of effective drugs or increasing resistance against the
few affordable drugs available.1 American trypanosomiasis,
also known as Chagas disease, is one of the most devastating
parasitic diseases. It is caused by the kinetoplastid protozoan
Trypanosoma cruzi, which is vectorially transmitted by a
hemiptera depositing feces on the skin surface, containing
metacyclic forms, after the blood meal. Other pathways of
infection include contaminated blood transfusions, organ
transplants, oral contamination caused by food/beverage,2,3
and even transmission from mother to child during pregnancy
or breastfeeding.4
Chagas disease manifests itself in the form of an acute
infection, during which most patients do not know that they
are infected. Actually, the acute phase can be asymptomatic
but also the Romana’s sign can be present in around 15% of
the cases. Only a 30– 40% of acute individuals undergo further
development and it becomes chronic and systemic, severely
affecting the heart, esophagus, and colon.5 Endemic through-
out Latin America, it is the third most widespread tropical
disease after malaria and schistosomiasis, according to the
World Health Organization (WHO).5
An estimated 10 million people are infected worldwide,
mostly inLatinAmericawhereChagasdisease is endemic.More
than 25 million people are at risk of the disease. It is estimated
that in 2008 Chagas disease killed more than 10,000 people6;
unfortunately, current treatment of this disease is very limited,
and no successful vaccine has been developed.7
Available drugs are mainly nitroheterocyclic compounds
such as nitrofuranenifurtimox or the nitroimidazole derivative
benznidazole (BZN), but they have proved effective only against
the acute phase, exhibiting very limited efficacy in the chronic
stage.8 Furthermore, they are quite toxic, causing severe side
effects such as pancreatitis and cardiac toxicity.2 The search
for more effective drugs focuses mainly on their potential action
over essential and exclusive components of the trypanosomatids.
The use of natural products as new chemotherapeutic
agents has been investigated for some time. Among these,
terpenoids, an important group of secondary metabolites,
must be emphasized, mainly because of their structural diver-
sity and natural abundance. During the last few years try-
panocidal activities for some triterpenes9 and diterpenes, with
ent-kaurene,10 pimarane,11 and spongiane skeleton,12 have
been reported. Recently, the trypanocidal activity of several
oxygenated abietane diterpenoids has been described.13 Diterpene
resin acids are important defense compounds from conifers
against potential herbivores and pathogens.14 The biological
activity of natural abietane acids has been reviewed.15 In recent
years, interest in these types of terpenoids has increased as a
result of the isolation of compounds, mainly phenols and related
derivatives, showing remarkable biological activities.16–18 Other
significant oxidized abietane diterpenes have shown strong
inhibition of various human tumors and oncogen-transformed
cells.19 The widespread use of these agents has not yet been
established, however, and chemotherapeutic armament against
kinetoplastic parasites remains limited. New drug options are
clearly needed to fight these pathogens.
Recently, our group synthesized abietane phenols 1–420,21
(Figure 1), and their antiproliferative in vitro and in vivo
activities against T. cruzi (epimastigote, amastigote, and
trypomastigote forms) have been investigated in this work.
Unspecific mammal cytotoxicity of the most active com-
pounds was evaluated in vitro, and less toxic derivatives
have been submitted to in vivo experimentation in a more
thorough study. Furthermore, we also included a nuclear
magnetic resonance (1H NMR) study concerning the nature
and percentage of the excretion metabolites to gain informa-
tion concerning the inhibitory effect of our compounds over
the glycolytic pathway, because it represents the prime source
of energy for the parasite. Finally, the effect of compounds
on the ultrastructure of T. cruzi is considered the basis of
transmission electronic microscopy (TEM) experiments.
MATERIALS ANDMETHODS
Chemical compounds. Compound 1, the methyl ester of
12-hydroxydehydroabietic acid, recently described as a new
*Address correspondence to Manuel Sa´nchez-Moreno, Department
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natural product,22 has been synthesized from commercial
abietic acid.20
Compounds 2–4 were prepared from trans-communic acid,21
a labdane diterpene very abundant in some species of
Juniperus and Cupressus. Compound 3 is the methyl ester
of lambertic acid, isolated from Podocarpus lambertius
and compound 4, 6,7-dehydroabieta-8,11,13-trien-12,19-diol,
named sugikurojin A, is a new diterpene recently isolated
from Cryptomeria japonica. Compound 2, methyl 12,15-
dihydroxyabieta-8,11,13-trien-19-oate, has not yet been found
in nature.
Parasite strain, culture. Trypanosoma cruzi SN3 strain of
(IRHOD/CO/2008/SN3) was isolated from domestic Rhodnius
prolixus and the biological origin is Guajira (Colombia).23
Epimastigote forms were obtained in biphasic blood-agar
NNN medium (Novy-Nicolle-McNeal) supplemented with
minimal essential medium and 20% inactivated fetal bovine
serum and afterwards reseeded in a monophasic culture
(MTL), following the method of Luque and others.24
Cell culture and cytotoxicity tests. Vero cells (Flow) were
grown in RPMI (Gibco, Madrid, Spain) supplemented with
l0% inactivated fetal bovine serum and adjusted to pH 7.2, in
a humidified 95% air-5% CO2 atmosphere at 37
C for 2 days.
For the cytotoxicity test, cells were placed in 30 mL sterile
polystyrene container (Deltalab, Barcelona, Spain), and
centrifuged at 100 g for 5 min. The culture medium was
removed, and fresh medium was added to a final concen-
tration of 1 + 10
5 cells/mL. This cell suspension was distrib-
uted in a culture tray (with 24 wells) at a rate of 100 mL/well
and incubated for 2 days at 37C in humid atmosphere
enriched with 5% CO2.
The medium was removed, and the fresh medium was added
together with the product to be studied (at concentrations of
100, 50, 25, l0 and 1 mM). After 72 h of treatment, the cell
viability was determined by flow cytometry. Thus, 100 mL/well
of propidium iodide (PI) solution (100 mg/mL) was added
and incubated for 10 min at 28C in darkness. Afterward,
100 mL/well of fluorescein diacetate (FDA) (100 ng/mL) was
added and incubated under the same conditions as above.
Finally, the cells were recovered by centrifugation at 400 g
for l0 min and the precipitate washed with phosphate buffer
solution (PBS). Flow cytometric analysis was performed on a
FACS Vantageflow cytometer (Becton Dickinson, Madrid,
Spain). The live cells with their plasma membrane intact were
associated with the green fluorescence, because of the effect of
sterases on FDA. On the other hand, cells that had lost the
membrane integrity and were dead allowed the penetration of
the IP by passive diffusion and specifically bound to their
DNA and then, fluoresce in the range of 580 nm. The percent-
age of viability was calculated in comparison to that of the
control culture (infected but untreated cultures), and the IC50
(the concentration required to give 50% of inhibition) was
calculated by linear-regression analysis from the Kc values at
the concentrations used.
In vitro trypanocidal activity assay. Epimastigote assay.
The parasite suspension was obtained for the trypanocidal
assay by concentrating the epimastigote culture in the expo-
nential growth phase by centrifugation at 1,000 g for 10 min,
whereupon the number of flagellates were counted in a
hemocytometric chamber and distributed into aliquots of
5 + 10
5 parasites/mL. The compounds were dissolved in dimethyl
sulfoxide at a concentration of 0.01%, after being assayed
as non-toxic and without inhibitory effects on the parasite
growth. The compounds were dissolved in the culture medium,
and the dosages used were 100, 50, 25, 10, and 1 mM.After 72 h
of incubation, the effect of each compound was evaluated by
light microscopy, through the quantification of viable parasite
using a Neubauer chamber.
Metacyclic trypomastigotes assay. Metacyclogenesis was
induced by culturing parasites at 28C in modified Grace’s
medium (Gibco) for 12 days as described previously.25
Twelve days after cultivation at 28C, metacyclic forms were
counted to infect Vero cells. The proportion of metacyclic
forms was around 40% at this stage.
After the metacyclic forms were obtained, Vero cells were
cultured in RPMI medium in a humidified 95% air-5% CO2
atmosphere at 37C. Cells were seeded at a density of 1 +
104 cells/well in 24-well microplates (Nunc, Roskilde, Denmark)
with rounded coverslips on the bottom and cultivated
for 2 days. Afterward, the cells were infected in vitro with
metacyclic forms of T. cruzi at a ratio of 10:1. The compounds
(IC25 concentrations, concentration required to give 25% of
inhibition) were added immediately after infection and were
incubated for 12 h at 37C in a 5%CO2. The non-phagocytosed
parasites and the drugs were removed by washing, and the
infected cultures were then grown for 10 days in fresh
medium without drugs. Fresh culture medium was added
every 48 h.
The activity of the compounds was determined from the
percentage of infected cells and the number of amastigotes
founded per cells infected in treated and untreated cultures in
methanol-fixed and Giemsa-stained preparations. The per-
centage of infected cells and the mean number of amastigotes
per infected cell were determined by analyzing more than
100 host cells distributed in randomly chosen microscopic
fields. Values are the means of three separate determinations.
The number of trypomastigotes in the medium was deter-
mined as described previously.24
Axenic amastigotes assay. Axenic amastigote forms of
T. cruzi were cultured following the methodology described
Figure 1. Terpenoid derivatives structure.
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previously by Moreno.26 Thus, epimastigotes transformed into
amastigotes after 3 days of culture inM199medium (Invitrogen,
Leiden, The Netherlands) supplemented with 10% heat-
inactivated FCS, 1 g/L b-alanine, 100 mg/L L- asparagine,
200 mg/L sucrose, 50 mg/L sodium pyruvate, 320 mg/L malic
acid, 40 mg/L fumaric acid, 70 mg/L succinic acid, 200 mg/L
a-ketoglutaric acid, 300 mg/L citric acid, 1.1 g/L sodium bicar-
bonate, 5 g/L MES, 0.4 mg/L hemin, and 10 mg/L gentamicin
pH 5.4 at 37C. The effect of each compound against 1 +
106 axenic amastigote forms/mL, was tested at 48 h using a
Neubauer hemocytometric chamber. The inhibitory effect is
expressed as IC50 values.
In vivo trypanocidal activity assay. This experiment was
performed with the permission of the ethical committee of the
University of Granada, Spain. Groups of three BALB/c female
mice (6 to 8 weeks of age; 25 g) maintained under standard
conditions were infected with 1 + 10
5 T. cruzimetacyclic forms
by the intraperitoneal route. The animals were divided into the
following groups: i) group 1: uninfected (not infected and not
treated); ii) group 2: untreated (infected with T. cruzi but not
treated); iii) group 3: uninfected (not infected and treated: with
1 mg/kg of body weight/day, for five consecutive days (7–
11 post-infection) by the intraperitoneal route27; and iv) group 4:
treated (infected and treated with 1 mg/kg of body weight/day
for five consecutive days (7 to 11 post-infection) by the intra-
peritoneal route with the compounds and BZN).
Treatments were started 7 days after infection with the
parasites. Compounds were administered in a similar way to
that explained previously and at the same concentrations.
A blood sample (5 mL) drawn from the mandibular vein of
each treated mouse was taken and diluted 1:15 (50 mL of
citrate buffer and 20 mL of lysis buffer at pH 7.2). The parasites
were counted by fields with the immersion objective. The num-
ber of bloodstream T. cruzi metacyclic forms were recorded
every 2 days from 7 to 40 days post-infection. The number of
metacyclic forms was expressed per 100 microscopic fields.
Circulating anti-T. cruzi antibodies were quantitatively
evaluated at Days 40 and 120 post-infection by the use of an
enzyme-linked immunoassay. The blood, diluted to 1:50 in
PBS, was reacted with an antigen constituted by a soluble
Fe-SODe from T. cruzi epimastigotes. The results are expressed
as the ratio of the absorbance (Abs) of each serum sample at
490 nm to the cutoff value. The cutoff for each reaction was
the mean of the values determined for the negative controls
plus three times the standard deviation.28
Metabolite excretion. Cultures of T. cruzi epimastigotes
(initial concentration 5 + 10
5 cells/mL) received IC25 of the
compounds (except for control cultures). After incubation for
96 h at 28C, the cells were centrifuged at 400 g for l0 min. The
supernatants were collected to determine excreted metab-
olites by 1H-NMR spectroscopy as previously described.29
The chemical displacements were expressed in parts per
million (ppm), using sodium 2,2 dimethyl-2-silapentane-5-
sulfonate as the reference signal. The chemical displacements
used to identify the respective metabolites were consistent
with that described.29
Ultrastructural alterations. The parasites, at a density of
5 + 10
5 cells/mL, were cultured in their corresponding medium,
containing the drugs at the IC25 concentration. After 96 h, the
cultures were centrifuged at 400 g for 10 min, and the pellets
washed in PBS and then fixed with 2% (v/v) p-formaldehyde-
glutaraldehyde in 0.05M cacodylate buffer (pH 7.4) for 5 h
at 4C. Pellets were prepared for TEM (Zeiss model,
Barcelona, Spain) following the technique of Luque.24
RESULTS
In vitro anti-T. cruzi and cytotoxicity evaluation. The inhibi-
tory effect of the new terpenoid Compounds 1–4 was mea-
sured at concentrations ranging from 1 to 100 mM on the
in vitro growth of. T. cruzi epimastigotes.30 The IC50 values
registered after 72 h of exposure are shown in Table 1, includ-
ing BZN as the reference drug. The trypanocidal activity of
the derivatives was slightly higher (Compounds 1 and 2, IC50
6.10 and 7.98 mM, respectively) or even slightly less (Com-
pounds 3 and 4, IC50 50.03 and 69.01 mM) with respect to
that found for BZN (15.89 mM).
The cytotoxicity evaluation against mammalian cells by
using Vero cells as the mammal-cell model (Table 1) showed
that the four derivatives were much less toxic than BZN.
On the other hand, the selectivity index calculated for the
derivatives was about 20-fold (Compound 1) and 24-fold
(Compound 2) higher than that of BZN. The SI values found
for Compounds 3 and 4 were significantly lower than those
found for Analogues 1 and 2.
Axenic amastigotes obtained following the technique
described in the Materials and Methods section, were assayed
to determine the IC50 against the four terpenoids, using BZN
as the reference drug (Table 1). Compounds 1 and 2 proved
the most effective with IC50 of 6.03 and 6.81 mM, respectively.
When the SI was determined for Compound 2, it was 32-fold
better than the reference drug, whereas Compound 1 was
23-fold better that the BZN again.
Table 1
In vitro activity, toxicity, and selectivity index found for the terpenoids derivatives on epimastigote and axenic-amastigote forms of
Trypanosoma cruzi*
Compound
Activity IC50 (mM)†
Toxicity on Vero cell IC50 (mM)‡
SI§
Epimastigote forms Axenic amastigote forms Epimastigote forms Axenic amastigote forms
Benznidazole 15.89  1.1 18.92  1.1 13.60  0.9 0.8 0.7
Compound 1 6.10  0.2 6.03  0.3 98.95  6.2 16.2 (20) 16.4 (23)
Compound 2 7.98  0.8 6.81  0.1 154.66  17.3 19.4 (24) 22.7 (32)
Compound 3 50.03  6.6 30.44  2.3 117.67  21.8 2.4 (3) 3.9 (6)
Compound 4 69.01  7.7 38.72  3.6 163.14  14.5 2.4 (3) 4.2 (6)
*Results are averages of three separate determinations.
† IC50 = the concentration required to give 50% inhibition, calculated by linear regression analysis from the Kc values at concentrations used (1, 10, 25, 50, and 100 mM).
‡On Vero cells after 72 h of culture. IC50 = the concentration required to give 50% inhibition, calculated by linear regression analysis from the Kc values at concentrations used (1, 10, 25, 50
and 100 mM).
§Selectivity index = IC50 Vero cells/IC50 epimastigote and axenic amastigote forms of the parasite. In brackets: number of times that compound SI exceeds the reference drug SI.
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Compounds 3 and 4 did not reach values of SI ³ 20-fold and
therefore these compounds were not included in the
subsequent studies.31
Because the metacyclic trypomastigote forms are responsi-
ble for the infection of the mammalian host, Compounds 1
and 2 were assayed against the metacyclic forms to evaluate
the infection rate. When 1 + 10
4 Vero cells were incubated
for 2 days and then infected with 1 + 10
5 metacyclic forms,
obtained in the way described in the Materials and Methods
section (control experiment; Figure 2A), the parasites invaded
the cells and underwent the morphological transformation to
amastigotes within 1 day after infection, following the para-
site’s normal life cycle. On Day 10, the rate of host-cell infec-
tion peaked. When Compounds 1 or 2 were added to the
infected Vero cells with T. cruzi metacyclic forms (IC25 con-
centration), the infection rate significantly decreased with
respect to the control, reaching 77% (Compound 1) and 82%
(Compound 2) on Day 10 of the experiment. The infection-
rate decline found using the compounds tested was substan-
tially more pronounced than that measured for BZN (39%).
Furthermore, another indication of the effectiveness of the
infection-rate decrease was the average number of amastigotes
per infected cell (Figure 2B) increased to 39.6 amastigotes/cell
in the control experiment on Day 6, decreased to a value of
30.6 on Day 8, and increased again to 35.0 on Day 10. The
break-up of Vero cells implies the transformation of amastigotes
into trypomastigotes and release to spread the infection. There-
fore, the variation of the trypomastigote number in the culture
medium was also measured (Figure 2C) as a third way to test
whether the infection rate was initially affected as a conse-
quence of the exposure to the compounds. The control experi-
ment afforded a trypomastigote number of 4.4 + 10
3 on Day 10,
and reductions of 37% and 55% are found for Compounds 1
and 2, respectively. The reduction was higher for Compound 2
than that found for BZN (35%).
In vivo anti-T. cruzi evaluation. The good results obtained
in vitro with Compound 1 and 2 prompted us to study their
in vivo activity in mice. Their impact on the two significant
stages of Chagas disease was evaluated: the acute phase, con-
sidered until 60 days post-infection, and the chronic phase,
from 60 days post-infection. It has been published that the
intravenous doping route results in high mortality rates,27
and therefore we used the intraperitoneal route, using a con-
centration of 5 mg/kg,32 which did not result in any animal
mortality. Female Swiss mice were inoculated intraperitone-
ally with 1 + 10
5 metacyclic trypomastigotes, and treatment
began 7 days post-infection with the intraperitoneally route of
1 mg/kg/day of each compound for 5 days. Administration
was performed using a saline solution. A group treated in the
same manner with the vehicle (control) was included. During
the study of the acute-phase activity, the level of parasitemia
was determined every 2 days (Figure 3).
None of the animals treated with Compounds 1 and 2 died
during the treatment, whereas the surviving percentage of the
mice treated with BZN was 80%.
The data represented in Figure 3 show that the two com-
pounds tested diminished the trypomastigote number on the
day of maximum parasitic load, which was Day 25 post-
infection, with respect to the control with untreated mice. On
Day 40 post-infection a reduction of the parasitemia was
found for the two compounds. From these data, the following
order for in vivo activity could be established: Compound 1 
Compound 2 > BZN.
Concerning the activity in the chronic phase, serological
tests were performed 40 and 120 days post-infection (Table 2).
Compounds 1 and 2 decreased antibody levels between
Days 40 and 120, showing higher performance than did BNZ
in this assay.
Studies on the action mechanism. To gain information on
the possible mechanism of action of Compounds 1 and 2 on
the parasite, we performed the following experiments:
Metabolite-excretion effect. For information concerning
the effect of Compounds 1 and 2 on metabolite excretion, the
1H-NMR spectra were registered. As a control, a culture
of parasites untreated was used (Figure 4A). In this control
experiment, T. cruzi excreted acetate and succinate as the
major metabolites and, in a lower percentage, L-alanine.
These data agree with those reported previously.33 When the
Figure 2. Effect of activity of terpenoid compounds on the
infection rate and T. cruzi growth. (A) Rate of infection. (B) Mean
number of amastigotes per infected Vero cell. (C) Number of
trypomastigotes in the culture medium. Control (-▲-); benznidazole
(BZN) (-○-); Compound 1 (-△-) and Compound 2 (-•-) (at IC25
conc.). The values are means of three separate experiments.
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trypanosomatids were treated with Compound 2, the excre-
tion of some of these catabolites (mainly acetate) was clearly
disturbed (Figure 4B) at the dosages assayed (IC25). Similarly,
succinate, L-alanine and ethanol levels rose in comparison
with the control experiment.
Compound 1 provoked similar effects, although at a lesser
magnitude (spectra not shown). The BZN did not trigger any
alteration in the energy metabolism of the parasites (spectra
not shown).
Ultrastructural alterations. The study of the ultrastructural
alterations caused by Compounds 1 and 2 in the T. cruzi
epimastigotes reflected notable changes in parasites, as
reflected in (Figure 5B, C, and D), with respect to the control
cultures (Figure 5A). Both compounds induced ultrastruc-
tural alterations. The most evident changes were the destruc-
tion of the treated parasites. Furthermore, there was evident
intense vacuolization in a high number of parasites. Com-
pound 2 triggered the dilatation of the kinetoplast of some
parasites (Figure 5D).
DISCUSSION
In most studies on activity assays of new compounds
against parasites, forms that develop in invertebrate host are
used because they are easier to handle in vitro, but a pre-
liminary test using extracellular epimastigote forms should
always be complemented by a subsequent evaluation using
Figure 3. Parasitemia in the murine model of acute Chagas disease. Control (-▲-) and dose receiving 5 mg/kg of: Benznidazole (BZN) (-○-);
Compound 1 (-△-) and Compound 2 (-•-). The values are means of three separate experiments.
Table 2
Differences in the level of anti-Trypanosoma cruzi antibodies
between Days 40 and 120 post-infection for Compounds 1 and 2
and benznidazole (BZN), expressed in absorbance units (abs)
Compounds* A†
Control (untreated) 0,206  0.07
BZN 0,116  0.03
Compound 1 0.237  0.01
Compound 2 0.005  0.00
*1 mg/kg/day, intraperitoneal route administered during 5 days (see Material and Methods).
†△A = absorbance at 490 nm, Day 120 p.i. absorbance at 490 nm, day 40 p.i.
Figure 4. Nuclear magnetic resonance (1H-NMR) spectra
epimastigote forms of Trypanosoma cruzi treated against terpenoids
compounds (at a concentration of IC25): (A) Control (untreated)
and (B) Compound 2. Ala = L-alanine; Ac = acetate; S = succinate;
Eth = ethanol, and DMSO = Dimethyl sulfoxide.
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intracellular forms (amastigotes in vertebrate host cells) for
a better understanding of the activity results found. For this
reason, we studied the activity of axenic amastigote forms.
The data on the axenic amastigotes match those found for
the extracellular forms, where Compounds 1 and 2 were the
most effective.
The trypanocidal effect of terpenoid compounds against
epimastigote and amastigote forms, has been previously shown.
Cassane diterpenes isolated from leaves of Myrospermum
frutescens, have anti-T. cruzi activity against these forms.34
According to the activity criteria for the development of
new drugs,31 only the compounds that SI ³ 20-fold were
included in the following studies.
The assays showed that Compounds 1 and 2 were effective
enough to undergo the next stage. To study the drug’s effect on
the infective parasite forms, we performed the metacyclic
assay. The IC25 of each product was used as the test dosage.
This concentration was chosen for being harmful but not totally
lethal,35 revealing that Compound 2 was the most effective.
Diterpenes isolated from Aristolochia cymbifera have been
shown to be selective against trypomastigotes.36
The in vivo assays showed that the differences in the
level of anti-T. cruzi antibodies are consistent with the
parasitemia findings.
As far as is known, no trypanosomatid studied to date
is capable of completely degrading glucose to CO2 under
Figure 5. Ultrastructural alterations by transmission electron microscopy (TEM) in Trypanosoma cruzi treated with terpenoids compounds.
(A) Control parasite of T. cruzi with structures as vacuoles (V) and mitochondrion (M), kinetoplast (K), glycosomes (G), and microtubules (MI)
(Bar: 583 mm). (B) Epimastigotes of T. cruzi treated with Compound 1 with cellular debris from dead parasites (CR) and vacuoles (V) (Bar: 1.59 mm).
(C and D) Epimastigotes of T. cruzi treated with Compound 2 with cellular rest (CR), vacuoles (V), and swelling kinetoplast (K) (Bar: 1.00 mm
and Bar: 583 mm, respectively).
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aerobic conditions, and thus these parasites excrete into the
medium a great part of their carbon skeleton as fermented
metabolites, which differ depending on the species consid-
ered.37,38 Trypanosoma cruzi consumes glucose at a high rate,
thereby acidifying the culture medium caused by incomplete
oxidation to acids. The 1H-NMR spectra enables us to
determine the fermented metabolites excreted by the try-
panosomatid during in vitro culture. One of the major metab-
olites excreted by T. cruzi is succinate, the main role of
which is probably to maintain the glycosomal redox balance,
by providing two glycosomal oxidoreductase enzymes that
allow reoxidation of NADH, produced by glyceraldehydes-3-
phosphate dehydrogenase in the glycolytic pathway. Succinic
fermentation offers the significant advantage of requiring
only half of the phosphoenolpyruvate produced to maintain
the NAD+/NADH balance. The remaining phosphoenol-
pyruvate is converted into acetate, L-lactate, L-alanine, and/or
ethanol, depending on the species considered. The role of the
acetate is probably to maintain the glycosomal redox balance.
In the case of Compound 2 the inhibition of acetate excretion
explains the observed increase in succinate, L-alanine, and
ethanol production, probably because these compounds act
over any level in the energy metabolism, still unknown.
In conclusion, our results show that four new terpenoid
derivative compounds were active in vitro against both extra-
and intracellular forms of T. cruzi (in the order 2 > 1 > 3 > 4 >
BZN). These compounds are not toxic for the host cells and
are effective at concentrations lower than the reference drug
used in this study. The in vitro growth rate of T. cruzi was
reduced, its capacity to infect cells was negatively affected,
and the multiplication of the amastigotes and subsequent
transformation into trypomastigotes was greatly lowered.
Moreover, a wide range of ultrastructural alterations in
epimastigote forms of T. cruzi treated with these new terpe-
noid compounds were found. These alterations mainly at the
mitochondria level could explain the metabolic changes in the
productions of succinate and acetate, which may be caused by
the disturbance of the enzymes involved in sugar metabolism
within the mitochondria. The in vivo studies revealed results
that were consistent with those observed in vitro. On the one
hand, during the treatment of mice with the compounds
(Compounds 1 and 2), no signs of toxicity were observed. On
the other hand, the parasitic load was significantly decreased
in comparison with the reference drug. The effects of these
products were also demonstrated with the anti-T. cruzi anti-
body level modification during the chronic stage. So far noth-
ing is known about the structure-activity relationship for
these substances, and the results described here do not allow
it. Additional research is needed for the activity of other
structurally related molecules. These results support further
research of terpenoid compounds as potential agents against
Chagas disease. The synthesis of new derivatives and preclini-
cal studies, such as doses, schedule, strains, and toxicological
studies, is currently in progress.
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